US Pharma MarketingASCO: Roche, head held high, details oral SERD's first-line flop in breast cancer
To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug giredestrant even as competition mounts. To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug giredestrant. Instead, the Swiss pharma has been inspired to open a new phase 3 study in the adjuvant setting. Pharma Vaccines Asia Cell & Gene Therapy Drug Delivery Executives Manufacturing Facilities Recalls Warning Letters Marketing Special Reports Fierce 50 Special Report Awards Gala Trending Oncology Supply Chain AI and Machine Learning Awards…
To Roche, a phase 3 flop in first-line breast cancer does not erase the megablockbuster potential of its oral SERD drug giredestrant. Instead, the Swiss pharma has been inspired to open a new phase 3 study in the adjuvant setting.
Source: FiercePharma